| Literature DB >> 28386165 |
Sheng Ye1, Dan Xu1, Chenmei Zhang1, Mengyao Li1, Yanyi Zhang2.
Abstract
Purpose. The study aimed to investigate the effectiveness of antipyretic therapy on mortality in critically ill patients with sepsis requiring mechanical ventilation. Methods. In this study, we employed the multiparameter intelligent monitoring in intensive care II (MIMIC-II) database (version 2.6). All patients meeting the criteria for sepsis and also receiving mechanical ventilation treatment were included for analysis, all of whom suffer from fever or hyperthermia. Logistic regression model and R language (R version 3.2.3 2015-12-10) were used to explore the association of antipyretic therapy and mortality risk in critically ill patients with sepsis receiving mechanical ventilation treatment. Results. A total of 8,711 patients with mechanical ventilator were included in our analysis, and 1523 patients died. We did not find any significant difference in the proportion of patients receiving antipyretic medication between survivors and nonsurvivors (7.9% versus 7.4%, p = 0.49). External cooling was associated with increased risk of death (13.5% versus 9.5%, p < 0.001). In our regression model, antipyretic therapy was positively associated with mortality risk (odds ratio [OR]: 1.41, 95% CI: 1.20-1.66, p < 0.001). Conclusions. The use of antipyretic therapy is associated with increased risk of mortality in septic ICU patients requiring mechanical ventilation. External cooling may even be deleterious.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28386165 PMCID: PMC5366196 DOI: 10.1155/2017/3087505
Source DB: PubMed Journal: Can Respir J ISSN: 1198-2241 Impact factor: 2.409
Comparisons between survivors and nonsurvivors.
| Variables | Overall ( | Survivors ( | Nonsurvivors ( |
|
|---|---|---|---|---|
| Age (years) | 66.1 (52.0, 77.5) | 64.6 (50.9, 76.6) | 71.3 (58.1, 81.2) | <0.001 |
| SAPS-1 | 17 (14, 20) | 16 (13, 20) | 19 (16, 23) | <0.001 |
| SOFA | 8 (6, 11) | 8 (6, 10) | 10 (7, 14) | <0.001 |
| Lactate level | 0.84 ± 0.76 | 0.85 ± 0.79 | 0.75 ± 0.62 | 0.0002 |
| Sex (male, %) | 4866 (55.9) | 4032 (56.1) | 834 (54.8) | 0.36 |
| Care unit type | <0.001 | |||
| MICU | 3567 (40.9) | 2801 (39.0) | 766 (50.3) | |
| SICU | 621 (7.1) | 546 (7.6) | 75 (4.9) | |
| CCU | 1646 (18.9) | 1293 (18.0) | 353 (23.2) | |
| CSRU | 2877 (33.0) | 2548 (35.4) | 329 (21.6) | |
| External cooling ( | 892 (10.2) | 686 (9.5) | 206 (13.5) | <0.001 |
| Drug cooling ( | 652 (7.5) | 531 (7.4) | 121 (7.9) | 0.49 |
| Any antipyretic ( | 1385 (15.9) | 1102 (15.3) | 283 (18.6) | 0.002 |
MICU, medical intensive care unit; SICU, surgical intensive care unit; CCU, coronary care unit; CSRU, cardiac surgery recovery unit; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment.
Logistic regression model adjusting for confounding factors of antipyretic therapy.
| Variables | OR | Lower limit | Upper limit |
|
|---|---|---|---|---|
| Age | 1.01 | 1.01 | 1.02 | <0.001 |
| SAPS-1 | 1.07 | 1.05 | 1.08 | <0.001 |
| SOFA | 1.13 | 1.11 | 1.15 | <0.001 |
| Female versus male | 1.05 | 0.93 | 1.19 | 0.438 |
| Care unit (versus MICU as reference) | ||||
| SICU | 0.66 | 0.50 | 0.86 | 0.003 |
| CCU | 0.92 | 0.78 | 1.07 | 0.273 |
| CSRU | 0.39 | 0.33 | 0.45 | <0.001 |
| Antipyretic therapy (any) | 1.41 | 1.20 | 1.66 | <0.001 |
OR, odds ratio; SAPS-1, Simplified Acute Physiology Score-1; SOFA, Sequential Organ Failure Assessment; MICU, medical intensive care unit; SICU, surgical intensive care unit; CCU, coronary care unit; CSRU, cardiac surgery recovery unit.
Figure 1
Figure 2
Figure 3Figure nomogram.